NGL Fine-Chem Limited (NSE:NGLFINE)

Market Cap	7.59B
Revenue (ttm)	3.82B
Net Income (ttm)	211.46M
Shares Out	n/a
EPS (ttm)	34.23
PE Ratio	35.92
Forward PE	n/a
Dividend	3.50 (0.26%)
Ex-Dividend Date	Aug 12, 2025

Volume	1,619
Average Volume	2,827
Open	1,260.50
Previous Close	1,260.60
Day's Range	1,201.00 - 1,268.20
52-Week Range	957.00 - 2,736.90
Beta	0.66
RSI	45.84
Earnings Date	Aug 1, 2025

About Aspen Technology

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltra...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1981
• Employees: 520
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: NGLFINE

Financial Performance

In 2024, NGL Fine-Chem's revenue was 3.68 billion, an increase of 8.73% compared to the previous year's 3.39 billion. Earnings were 211.24 million, a decrease of -48.87%.